Erlotinib hydrochloride CAS:183319-69-9

Erlotinib hydrochloride is employed in various therapeutic and research applications: Cancer Treatment: It is approved for the treatment of locally advanced or metastatic NSCLC and as a second-line treatment for advanced pancreatic cancer. The inhibition of EGFR signaling helps to slow down or stop the growth of cancer cells. Clinical Research: Researchers study its efficacy and safety in clinical trials for other types of cancers and as part of combination therapies with other anticancer drugs. Molecular Targeted Therapy: As a targeted therapy drug, erlotinib hydrochloride specifically targets cancer cells without harming normal cells, reducing side effects compared to traditional chemotherapy. Biomarker Studies: Used in studies aimed at understanding biomarkers associated with EGFR mutations and their impact on treatment response. Drug Development: Its success has spurred research into developing other EGFR inhibitors and improving treatment strategies for cancers driven by EGFR mutations. Personalized Medicine: Erlotinib hydrochloride exemplifies the shift towards personalized medicine, where treatments are tailored based on genetic characteristics of the patient and tumor. In conclusion, erlotinib hydrochloride is a pivotal drug in oncology, offering targeted therapy options for specific types of cancer, particularly those associated with EGFR mutations. Ongoing research continues to explore its full potential and expand its applications in cancer treatment and management.